Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


03 diciembre 2013

Hipotensión, la gran desconocida

Noticias Medicas

Aproximadamente entre el 30 y el 40% de la población mundial adulta sufre hipertensión arterial, responsable de enfermedades del corazón, derrames cerebrales u otras complicaciones de salud. En el otro lado de la moneda está la presión arterial baja (hipotensión). HARTMANN recomienda la medición de la presión arterial como prevención para potenciales problemas cardiovasculares.

25 noviembre 2013

Interim first-in-human data for bioengineered blood vessel presented

Vascular News

Humacyte has announced the presentation of interim, first-in-human data from an ongoing, multicentre study in Poland, evaluating the company’s investigational bioengineered blood vessel in haemodialysis patients with end-stage renal disease. The data were presented by Jeffrey H Lawson at the American Heart Association Scientific Sessions 2013 in Dallas, USA. Lawson is professor of Surgery and Pathology with tenure at Duke University Medical Center (Durham, USA), and director of the Vascular Research Laboratory and Director of Clinical Trials for the Department of Surgery. He is also clinical consultant to Humacyte.

23 octubre 2013

Excessive alcohol consumption increases the progression of atherosclerosis and the risk of stroke

MNT

A Finnish population-based study showed that binge drinking was associated with increased atherosclerotic progression in an 11-year follow-up of middle-aged men. The progression of atherosclerosis was increased among men who consumed 6 drinks or more on one occasion. In addition, the risk of stroke increased among men who had at least one hangover per year. Hangovers increased the risk of stroke independent of the total amount of alcohol consumed. Hypertension and overweight, in the presence of alcohol consumption, further increased the risk of stroke. Drinking large quantities of alcohol more than twice a week increased the risk of stroke mortality in men.

15 octubre 2013

For patients with diabetes, angioplasty and bypass surgery lead to similar long-term benefits for quality of life

MNT

For patients with diabetes and coronary artery disease in more than one artery, treatment with coronary artery bypass graft surgery provided slightly better health status and quality of life between 6 months and 2 years than procedures using drug-eluting stents, although beyond 2 years the difference disappeared, according to a study in the October 16 issue of JAMA.

21 octubre 2013

Low-fiber diet tied to higher cardiometabolic risk

MNT

A new US study that analyzed data from a large national survey has found a significant link between diets low in fiber and increased cardiometabolic risk, a cluster of risk factors that increases a person s chances of having diabetes, heart disease or stroke.

04 noviembre 2013

Samsung Announces US Commercial Release of Samsung XGEO GC80 Digital Radiography System

Healthcare Sales & Marketing Network

Samsung Electronics America Inc. announced today the U.S. commercial release of its first Digital Radiology (DR) system, the Samsung XGEO GC80. The Samsung XGEO GC80, which received 510(k) approval from the U.S. Food and Drug Administration earlier this year, represents Samsung’s entrance into the DR market with a premium system offering advanced imaging technology, award-winning* design and user-friendly workflows to meet the demands of the 21st century radiology departments.

07 noviembre 2013

Presentados alentadores datos de supervivencia en pacientes con cáncer de pulmón tratados con Nivolumab

Noticias Médicas

Bristol-Myers Squibb Company (NYSE: BMY) ha anunciado los resultados de seguimiento a largo plazo (mediana de seguimiento de 20,3 meses) de la cohorte de cáncer de pulmón (n=129) de la fase de extensión de fase 1 de búsqueda de dosis (003) de nivolumab, un inhibidor experimental del punto de control inmunitario PD-1. Los resultados demostraron que la actividad se mantenía en pacientes con cáncer de pulmón no microcítico (CPNM) altamente pretratados. En concreto, se observaron unas tasas de supervivencia a un año y a dos años del 42% y 24% respectivamente en todas las cohortes de dosis. Estos datos, que se basan en estimaciones de Kaplan-Meier, se han presentado en el 15º Congreso Mundial sobre Cáncer de Pulmón (Abstract # MO18.03).

08 noviembre 2013

El equipo de Ginecología y Obstetricia del profesor Santiago Dexeus se incorpora a Sanitas Hospitales

Noticias Médicas

Barcelona, noviembre de 2013. El equipo de Ginecología y Obstetricia liderado por el econocido especialista profesor Santiago Dexeus se ha incorporado al cuadro médico de Sanitas Hospitales en Cataluña. El equipo ya ha iniciado las consultas en el Milenium Centro Médico Iradier y desarrollará su actividad quirúrgica en el Hospital Sanitas CIMA de Barcelona.

09 octubre 2013

Biotronik announces new product additions to its peripheral portfolio

Interventional News

On 2 October 2013, Biotronik announced the launch of the Passeo-35 0.035” OTW PTA balloon Line Extension and the Passeo-35 HP high pressure percutaneous transluminal angioplasty (PTA) balloon. The Passeo-35 0.035” OTW PTA balloon is now also available in lengths of up to 200mm and the Passeo-35 HP high pressure PTA balloon is designed for arteriovenous dialysis fistulae application.

30 octubre 2013

3-Year Data From Medtronic s SYMPLICITY HTN-2 Trial Presented

Endovascular Today

Medtronic, Inc. (Minneapolis, MN) announced the presentation of 3-year data from the SYMPLICITY HTN-2 at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California. SYMPLICITY HTN-2, a randomized, controlled clinical trial of renal denervation in patients with uncontrolled hypertension. These data demonstrate results consistent with data reported previously at 6, 12, and 24 months of follow-up.

09 octubre 2013

Biotronik announces new product additions to its peripheral portfolio

Vascular News

On 2 October 2013, Biotronik announced the launch of the Passeo-35 0.035” OTW PTA balloon Line Extension and the Passeo-35 HP high pressure percutaneous transluminal angioplasty (PTA) balloon. The Passeo-35 0.035” OTW PTA balloon is now also available in lengths of up to 200mm and the Passeo-35 HP high pressure PTA balloon is designed for arteriovenous dialysis fistulae application.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.